 |
|
|
| |
Initiating long-acting cabotegravir and rilpivirine in a real-world setting: clinical
characteristics and switch reasons from PLHIV and health care provider
perspective in the German CARLOS cohort
|
| |
| |
AIDS 2022 July 29-Aug 1 Montreal
Christoph Wyen,1 Jenny Scherzer,2 Celia Jonsson-Oldenbuttel,3 Christian Lieb,4 Kevin Ummard-Berger,5 Christiane Cordes,6 Nils Postel,7
Samia Dakhia,8 Bernd Westermayer,9 Katharina Bernhardt2
1Praxis Ebertplatz, Cologne, Germany; 2ViiV Healthcare, Munich, Germany; 3MVZ München am Goetheplatz, Munich, Germany; 4Praxis Goldstein, Berlin, Germany; 5UBN / Praxis, Berlin, Germany;
6Praxis Dr. Cordes, Berlin, Germany
; 7prinzmed, Munich, Germany; 8ViiV Healthcare, Brentford, London UK; 9GlaxoSmithKline, Munich, Germany
|
| |
|
|
|
|
|
